This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager.
Dismiss

Merck Sharp & Dohme's patent upheld by EPO's Board of Appeal

( December 3, 2024, 13:31 GMT | Official Statement) -- MLex Summary: European Patent Office's Technical Board of Appeal upheld Merck Sharp & Dohme's patent in amended form, rejecting opposition raised by patent law firm König, Szynka, Tilmann, von Renesse. The law firm appealed against the interlocutory decision of the EPO's Opposition Division to uphold Merck's European patent 2,691,112 relating to stable formulations of pembrolizumab, which is used in therapeutic treatment. The appeal requested the patent revocation in its entirety, arguing the patent wasn't innovative. However, the board concluded that the patent involved an inventive step as per Article 56 of the European Patent Convention.The document is attached. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections